What Carbenoxolone Treats: Main Uses and Benefits

Carbenoxolone is an agent primarily used in situations involving certain distressing symptoms associated with gastrointestinal and oral lesions, notably digestive tract ulcers, especially in the stomach. It is applied across domains where additional symptomatic support is needed, helping to address groups of symptoms that may appear suddenly or intensify over time, such as pain and localized inflammation. The therapeutic domains often involve managing symptoms associated with peptic (gastric and duodenal) ulcers, esophageal ulcers, and mouth ulceration.

This medication is applicable in conditions characterized by periods of heightened symptoms, particularly those involving recurrent or episodic ulcerations. It is relevant when supportive symptom management is appropriate, as it is used to help with managing symptoms that interfere with daily comfort. As a result, it helps patients cope more steadily with difficult episodes.

“It is often used when symptoms intensify and short-term symptomatic assistance is needed for managing symptoms that are linked to organ-specific functional stress.”

Key Focus: Symptomatic support for inflammation and pain linked to ulcers.

Regulatory References

1. National Institutes of Health MeSH database

Carbenoxolone's official eligibility profile is strictly defined by regulatory documents that impose absolute prohibitions on its use in specific populations. The medicine is contra-indicated in patients with severe, pre-existing organ dysfunction, including severe cardiac impairment, severe renal impairment, or severe hepatic impairment. Use is also officially forbidden for patients with existing hypertension (high blood pressure).

Age-related restrictions designate children under 3 years and elderly patients as contra-indicated populations. Additional prohibitions apply to individuals with certain clinical statuses: the drug is contra-indicated in patients with low serum albumin and those concurrently taking cardiac glycosides. Furthermore, official labeling states that Carbenoxolone is contra-indicated for use during pregnancy and lactation. Only adults and children over 3 years who are free of these specific high-risk conditions are defined as the eligible population.

Interactions with other medicines and products

Official regulatory documentation details the specific interactions that arise from Carbenoxolone's mineralocorticoid-like activity, primarily impacting electrolyte balance and pharmacodynamic response.

Formally Documented Contraindications and Restrictions

Clinically Significant Pharmacodynamic Interactions

Co-administration with several classes of medicine is documented to reinforce or antagonize Carbenoxolone's effects. The combination with Diuretics (thiazide and loop types) and Adrenal Corticosteroids is noted to exacerbate the risk of hypokalaemia and related mineralocorticoid-like effects. Conversely, the use of Spironolactone or Amiloride is associated with a formal antagonism of therapeutic efficacy.

Pharmacokinetic and Population-Specific Notes

Interaction notes include the potential for Chlorpropamide to cause delayed absorption. Regulatory information also specifies that the severity of interaction effects, particularly those related to electrolyte imbalance, is formally heightened in elderly patients and considered more clinically significant in those with severe renal or hepatic impairment.

Carbenoxolone functions as a non-selective inhibitor of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) enzymes, primarily targeting the Type 1 isozyme (11beta-HSD1) and, to a lesser extent, the Type 2 isozyme (11beta-HSD2). In tissues expressing 11beta-HSD2, such as the renal collecting duct and gastrointestinal tract, its inhibitory action blocks the enzyme's conversion of active cortisol to inactive cortisone. This antagonism of 11beta-HSD2 increases the local bioavailability of cortisol, leading to the activation of mineralocorticoid receptors (MR), which have a high affinity for glucocorticoids when 11beta-HSD2 is inhibited. The subsequent MR signaling cascade includes upregulation of the epithelial sodium channel (ENaC) and the Na^+/ K^+-ATPase pump in renal tubules. This downstream effect promotes sodium reabsorption and potassium excretion in the kidney. Carbenoxolone also acts as a non-specific blocker of gap junctions, which are intercellular channels formed by connexin proteins. This interaction modifies direct cell-to-cell communication and electric coupling across multiple tissues.

How to Use Carbenoxolone: Administration Guidelines

Carbenoxolone is administered via distinct routes depending on the target site, based on standard clinical parameters that define the dosage, frequency, and duration of use.

Administration Routes and Dosing Patterns

The medication is available for oral use in the form of tablets or capsules, and for topical use as a 2% gel or cream. This dual availability dictates two separate administration protocols. For gastrointestinal applications, the oral route is used with a common adult dosing regimen starting at 100 mg three times daily. For localized oral lesions, a 2% topical formulation is applied directly.

Frequency, Timing, and Duration

Oral use requires divided daily dosing, typically administered two to four times per day, and is prescribed for a defined treatment course, generally spanning four to six weeks. This period reflects the intended duration for the resolution of acute conditions. For the topical gel, application is prescribed four times daily. Instructions for the topical route emphasize that the gel must be applied after meals and at bedtime. This specific timing aims to maximize the duration of contact between the drug and the mucosal lesion, thereby ensuring optimal use of the localized preparation. Topical use is constrained to a shorter duration; if symptoms persist beyond two weeks, the patient should seek reassessment.

Special Administration Constraints

The topical formulation is restricted to oromucosal and cutaneous application only and must not be ingested for a systemic effect. Furthermore, the 2% topical gel is generally limited to use in adults and children over 3 years of age, establishing a clear age-specific constraint on administration. Lower dosages are advised for oral formulations in older adults where appropriate, reflecting population-specific use considerations.

Research Evidence / Overview of Studies for Carbenoxolone

Evidence for Use in Benign Gastric Ulceration

Carbenoxolone was studied for its use in benign gastric ulceration, which relates to ulcers located in the stomach lining. Studies that explored this application include short-term Randomized Controlled Trials (RCTs) and double-blind trials, as well as comparative clinical trials. Research examined measurements of ulcer healing rates, assessed using endoscopy, and monitored patient-reported outcomes describing perceived discomfort and symptoms related to physical discomfort. These studies primarily applied to adult outpatients who had endoscopically confirmed ulcers.

Studies focusing on episodes where symptoms become more noticeable reported findings that included measurements of ulcer healing, with patterns observed in the studied groups. The findings help contextualize how patients reported their experience when the compound was studied for conditions characterized by fluctuating manifestations. Comparative evidence is lacking against some contemporary anti-ulcer treatments.

Evidence for Use in Other Peptic Ulcers and Oral Lesions

Carbenoxolone was also evaluated in studies exploring its application in other areas of the digestive tract and mouth. Research examined outcomes related to physical discomfort, such as the time required for the lesion or ulcer to heal, and the reduction in reported localized pain. Findings were observed in some studies for duodenal ulcers, but the volume of evidence for this indication is less extensive than research for gastric ulcers.

Long-Term Studies and Follow-up Duration

When Carbenoxolone was evaluated in studies for ulcer healing, the follow-up durations were limited, typically focused on a short-term period of 4 to 6 weeks. Research explores short-term symptom changes, but long-term effects are not fully established. There is limited information for long-term outcomes, such as the durability of the healing effect or the persistence of recurrence rates beyond the short observation window.

What Is Still Uncertain About Carbenoxolone Research

Data for certain groups remain insufficient; research for populations such as children or those with various comorbid conditions is limited. The sample sizes were modest in many of the studies exploring healing patterns, and the age of the key research means that the study results reflect the specific conditions under which they were conducted. Furthermore, comparative evidence is lacking against some newer therapies. Evidence highlights what is known—and what is still uncertain—meaning research provides context but not individual predictions.

Common questions about Carbenoxolone (FAQ)

Q: Can Carbenoxolone be given to children?

Official product information contra-indicates the use of the medicine in children under 3 years old. For the topical gel formulation, official documents describe its use for adults and children over 3 years of age. Eligibility is addressed by official regulatory documents, which note specific age and condition-based restrictions.

Q: What should I do if I experience muscle weakness while taking Carbenoxolone?

Muscle weakness is a documented common side effect associated with low potassium levels (hypokalaemia) caused by the medicine. Regulatory documents mention that persistent symptoms or changes in health are typically reviewed by a healthcare professional.

Q: Does Carbenoxolone need to be taken before or after food?

The timing for using the medicine varies by the form used. For the oral tablet formulation, some product information describes use before meals. For the topical gel, official instructions require that it be applied after meals and again at bedtime.

Q: Is it true that Carbenoxolone is derived from licorice?

Carbenoxolone is a synthetic chemical derivative of glycyrrhetinic acid, which is a compound found in natural licorice root. It is described in authoritative sources as being structurally related to glycyrrhizin, the primary compound found in licorice.

Q: What is the risk of Carbenoxolone causing heart problems?

Official documentation indicates a risk of serious adverse reactions, which include congestive cardiac failure. This risk is primarily linked to the effect of sodium and water retention caused by the medicine, which increases fluid volume.

Q: Why does Carbenoxolone sometimes cause fluid retention?

Carbenoxolone’s effects include causing the kidney to reabsorb sodium. This physiological change, in turn, can cause the body to retain sodium and water, which is a commonly reported adverse reaction.

Q: Is Carbenoxolone considered a steroid?

Carbenoxolone is chemically classified as a triterpenoid derivative and an anti-ulcer agent. While official sources describe it as having a steroid-like chemical structure and exhibiting mineralocorticoid-like activity, it is not classified as a standard corticosteroid medicine.

Q: Are there different strengths or formulations of Carbenoxolone available?

Yes, Carbenoxolone has been available in various forms depending on the target site. These include forms for oral administration, such as tablets and capsules (commonly 100 mg), and specialized preparations for topical use, such as oral gels (e.g., 2% concentration) or mouthwash.

Q: Is Carbenoxolone used for acid reflux (GERD)?

Authoritative databases indicate that Carbenoxolone is used to treat conditions characterized by damage to the digestive tract lining. These indications include peptic ulcer and gastroesophageal reflux disease (GERD).

Q: What does the research say about Carbenoxolone and esophageal ulcers?

Authoritative sources and indication documentation describe Carbenoxolone as being indicated for various ulcerations and related inflammation in the upper digestive tract, which includes esophageal ulcers.

Q: What is the typical length of time a person uses Carbenoxolone?

According to official product information, the oral medication is prescribed for a defined treatment course. This duration typically spans four to six weeks and is intended for the resolution of acute conditions.

Q: Can I drive or operate machinery while taking Carbenoxolone?

Official product information for the topical gel formulation states that its use is unlikely to result in any impairment of the ability of patients to drive or operate machinery.

How to Store and Dispose of Carbenoxolone

Official regulatory documents define specific storage and disposal requirements for carbenoxolone, primarily focusing on maintaining the product's integrity and ensuring safety.

Storage Requirements

️ Disposal Instructions

Expired or unused carbenoxolone must not be thrown away via wastewater or general household waste. Disposal must follow mandatory environmental guidelines. You are instructed to ask your pharmacist how to properly discard any medicines you no longer use to help protect the environment.